Modeling genotype-protein interaction and correlation for Alzheimer's disease: a multi-omics imaging genetics study
Jin Zhang1, Zikang Ma1, Yan Yang1
1Department of Intelligent Science and Technology, Northwestern Polytechnical University School of Automation, 127 Youyi Road, 710072 Shaanxi, China.
Briefings in Bioinformatics
|February 13, 2024
Summary
This study introduces MT-GPIC, a novel method to untangle genotype-protein interactions and correlations in Alzheimer's disease (AD) omics data. It enhances understanding of AD's complex genetic and imaging links.
Area of Science:
- Neuroscience
- Genetics
- Biostatistics
Background:
- Alzheimer's disease (AD) research integrates genomics, proteomics, and radiomics for comprehensive understanding.
- Current methods often neglect non-additive effects like genotype-protein interactions (GPI) and correlation patterns in brain imaging genetics.
- These overlooked non-additive effects may significantly influence intermediate imaging phenotypes and disease progression.
Purpose of the Study:
- To address the unexploited challenge of disentangling genotype-protein interactions (GPI) from correlation patterns in brain imaging genetics.
- To introduce a novel computational method, Multi-Task Genotype-Protein Interaction and Correlation (MT-GPIC), for identifying GPI and extracting correlation patterns.
- To enhance the interpretability and stability of findings by utilizing novel penalties and considering brain region interconnectedness.
Main Methods:
- Development of the MT-GPIC method to simultaneously identify genotype-protein interactions and correlation patterns.
- Application of novel and off-the-shelf penalties for identifying meaningful genetic risk factors and exploiting brain region interconnectedness.
- Implementation of a fast, convergent optimization strategy to address the computational burden of calculating GPI.
Main Results:
- MT-GPIC demonstrated superior performance compared to state-of-the-art methods on the Alzheimer's Disease Neuroimaging Initiative dataset.
- The method achieved higher correlation coefficients and improved classification accuracy in AD-related analyses.
- MT-GPIC successfully identified interpretable, phenotype-related GPI and correlation patterns within high-dimensional omics data.
Conclusions:
- The developed MT-GPIC method effectively disentangles genotype-protein interactions and correlation patterns in AD research.
- Findings suggest that non-additive genetic and protein effects play a crucial role in AD pathogenesis and imaging phenotypes.
- This approach offers enhanced diagnostic accuracy and provides valuable insights into the underlying mechanisms of Alzheimer's disease.
Keywords:
biomarker identificationgenotype–protein interaction and correlationmulti-omics brain imaging geneticsMore Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35


